Immunogenetic features of HIV-infection and allergy comorbidity

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Today, the comorbidity of infection caused by the human immunodeficiency virus (HIV) is an important problem due to the complexity of the selection of the optimal antiretroviral therapy and the diagnosing of associated pathological conditions. The study of the comorbidity of HIV-infection and allergy is an important area of research. This article presents a literature review on different types of comorbidity. Special attention is paid to the development of allergic reactions to antiretroviral drugs. The presence of an allergic reaction in a patient can cause low adherence to therapy and subsequent development of HIV resistance to the treatment. The review provides information on the possible causes of the development of hypersensitivity in HIV-infected patients. The data on the development of hypersensitivity reactions in response to treatment with the main classes of antiretroviral drugs (nucleoside and non-nucleoside reverse transcriptase inhibitors, synthesis inhibitors, protease inhibitors, integrase inhibitors, cysteine-cysteine chemokine receptor 5 inhibitors) are presented. The most common allergic reactions to these drug classes are itching and rash, as well as increasing hepatic transaminase levels and cough. The existing scientific data on allergic reactions to drugs prescribed for other concurrent conditions (tuberculosis, fungal diseases) is also considered. The examples of studies reflecting the relevance of using immunogenetic and molecular genetic approaches in the study of comorbidity of HIV-infection and allergy are given. The identification of immunogenetic markers of the development of the hypersensitivity to therapy will optimize the diagnostic and treatment algorithms, especially in complex comorbid conditions.

Full Text

Restricted Access

About the authors

S A Nora

Yaroslav-the-Wise Novgorod State University

Author for correspondence.
Email: sergey.nora@novsu.ru
Russian Federation, Veliky Novgorod, Russia

G S Arkhipov

Yaroslav-the-Wise Novgorod State University

Email: sergey.nora@novsu.ru
Russian Federation, Veliky Novgorod, Russia

E I Arkhipova

Yaroslav-the-Wise Novgorod State University

Email: sergey.nora@novsu.ru
Russian Federation, Veliky Novgorod, Russia

N N Nikitina

Yaroslav-the-Wise Novgorod State University

Email: sergey.nora@novsu.ru
Russian Federation, Veliky Novgorod, Russia

References

  1. Marlink R., Kanki P., Thior I., Travers K., Eisen G., Siby T., Traore I., Hsieh C.C., Dia M.C., Gueye E.H., Hellinger J., Guèye-Ndiaye A., Sankalé J.-L., Ndoye I., Mboup S., Essex M. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994; 265 (5178): 1587–1590. doi: 10.1126/science.7915856.
  2. Duarte R., Lönnroth K., Carvalho C., Lima F., Carvalho A.C.C., Muñoz-Torrico M., Centis R. Tuberculosis, social determinants and co-morbidities (including HIV). Pulmono¬logy. 2018; 24 (2): 115–119. doi: 10.1016/j.rppnen.2017.11.003.
  3. Rockstroh J.K., Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect. Dis. 2004; 4 (7): 437–444. doi: 10.1016/S1473-3099(04)01059-X.
  4. Kupin W.L. Viral-associated GN: Hepatitis C and HIV. Clin. J. Am. Soc. Nephrol. 2017; 12 (8): 1337–1342. doi: 10.2215/CJN.04320416.
  5. Barreiro P., Martín-Carbonero L., García-Samaniego J. Hepatitis B en pacientes con infección por el virus de la inmunodeficiencia humana. Enferm. Infecc. Microbiol. Clin. 2008; 26 (Suppl. 7): 71–79. (In Spanish.) doi: 10.1016/s0213-005x(08)76522-4.
  6. Duncan A.D., Goff L.M., Peters B.S. Type 2 diabetes prevalence and its risk factors in HIV: A cross-sectional study. PLoS One. 2018; 13 (3): e0194199. doi: 10.1371/journal.pone.0194199.
  7. Getahun Z., Azage M., Abuhay T., Abebe F. Comorbidity of HIV, hypertension, and diabetes and associated factors among people receiving antiretroviral therapy in Bahir Dar city, Ethiopia. J. Comorb. 2020; 10: 2235042X19899319. doi: 10.1177/2235042X19899319.
  8. Mokronosova M.A., Mats A.N. Infection and allergies: two sides of the same coin. Astma i allergiya. 2015; (4): 9–12. (In Russ.)
  9. Akhmedzhanova Z.I. The incidence of allergic diseases in HIV-infected. Meditsinskaya immunologiya. 2009; 11 (4–5): 380. (In Russ.)
  10. Nora S.A., Arkhipov G.S., Kropachev I.G., Arkhipova E.I. Role of allergies in diagnostics and treatment of HIV-infection. Vestnik Novgorodskogo gosudarstvennogo universiteta. 2021; (1): 67–70. (In Russ.) doi: 10.34680/2076-8052.2021.1(122).67-70.
  11. Freidin M.V., Puzyrev V.P. Genomic bases of susceptibility to atopic diseases. Molekulyarnaya meditsina. 2007; (3): 26–35. (In Russ.)
  12. Hershey G.K.K., Friedrich M.F., Esswein L.A., Thomas M.L., Chatila T.A. The association of atopy with a gain of function mutation in the α-subunit of the interleukin 4 receptor. New Eng. J. Med. 1997; 337: 1720–1725. doi: 10.1056/NEJM199712113372403.
  13. Mitsuyasu H., Yanagihara Y., Mao X.Q., Gao P.S., Arinobu Y., Ihara K., Takabayashi A., Hara T., Enomoto T., Sasaki S., Kawai M., Hamasaki N., Shirakawa T., Hopkin J.M., Izuhara K. Dominant effect of Ile50Val variant of the human IL-4 receptor α-chain in IgE synthesis. J. Immunol. 1999; 162: 1227–1231. PMID: 9973373.
  14. Simonov R.O., Valishin D.A., Yapparov R.G. Acute allergies in HIV-infected patients against the background of helminthic invasion. In: Diagnostika i lechenie glaznykh proyavleniy infektsionnykh i sistemnykh zabolevaniy. (Diagnostics and treatment of ocular manifestations of infectious and systemic diseases.) 2018; 98–105. (In Russ.)
  15. Brown M., Mawa P.A., Kaleebu P., Elliott A.M. Helminths and HIV infection: epidemiological observations on immunological hypotheses. Parasite Immunol. 2006; 28 (11): 613–623. doi: 10.1111/j.1365-3024.2006.00904.x.
  16. Wolday D., Mayaan S., Mariam Z.G., Berhe N., Seboxa T., Britton S., Galai N., Landay A., Bentwich Z. Treatment of intestinal worms is associated with decreased HIV plasma viral load. J. Acquir Immune Defic. Syndr. 2002; 31 (1): 56–62. doi: 10.1097/00126334-200209010-00008.
  17. Means A.R., Burns P., Sinclair D., Walson J.L. Antihelminthics in helminth-endemic areas: effects on HIV disease progression. Cochrane Database Syst. Rev. 2016; 4 (4): CD006419. doi: 10.1002/14651858.CD006419.pub4.
  18. Walson J., Singa B., Sangaré L., Naulikha J., Piper B., Richardson B., Otieno P.A., Mbogo L.W., Berkley J.A., John-Stewart G. Empiric deworming to delay HIV disease progression in adults with HIV who are ineligible for initiation of antiretroviral treatment (the HEAT study): a multi-site, randomised trial. Lancet Infect. Dis. 2012; 12 (12): 925–932. doi: 10.1016/S1473-3099(12)70207-4.
  19. Chernikova E.A., Drynov G.I. Helminthiasis in the practice of an allergist. Astma i allergiya. 2016; (1): 27–32. (In Russ.)
  20. Davis C.M., Shearer W.T. Diagnosis and management of HIV drug hypersensitivity. J. Allergy Clin. Immunol. 2008; 121 (4): 826–832.e5. doi: 10.1016/j.jaci.2007.10.021.
  21. Peter J., Choshi P., Lehloenya R.J. Drug hypersensitivity in HIV infection. Curr. Opin. Allergy Clin. Immunol. 2019; 19 (4): 272–282. doi: 10.1097/ACI.0000000000000545.
  22. Borrás-Blasco J., Navarro-Ruiz A., Borrás C., Casterá E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J. Antimicrob. Chemother. 2008; 62 (5): 879–888. doi: 10.1093/jac/dkn292.
  23. Yunihastuti E., Widhani A., Karjadi T.H. Drug hypersensitivity in human immunodeficiency virus-infec¬ted patient: challenging diagnosis and management. Asia Pac. Allergy. 2014; 4 (1): 54–67. doi: 10.5415/apallergy.2014.4.1.54.
  24. Verma R., Vasudevan B., Shankar S., Pragasam V., Suwal B., Venugopal R. First reported case of tenofovir-induced photoallergic reaction. Indian J. Pharmacol. 2012; 44 (5): 651–653. doi: 10.4103/0253-7613.100407.
  25. Temesgen Z., Beri G. HIV and drug allergy. Immunol. Allergy Clin. North Am. 2004; 24 (3): 521–531. doi: 10.1016/j.iac.2004.03.006.
  26. Montessori V., Press N., Harris M., Akagi L., Montaner J.S. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004; 170 (2): 229–238. PMID: 14734438.
  27. Squires K., Lazzarin A., Gatell J.M., Powderly W.G., Pokrovskiy V., Delfraissy J.F., Jemsek J., Rivero A., Rozenbaum W., Schrader S., Sension M., Vibhagool A., Thiry A., Giordano M. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir Immune Defic. Syndr. 2004; 36 (5): 1011–1019. doi: 10.1097/00126334-200408150-00003.
  28. Madruga J.V., Berger D., McMurchie M., Suter F., Banhegyi D., Ruxrungtham K., Norris D., Lefebvre E., de Béthune M.P., Tomaka F., De Pauw M., Vangeneugden T., Spinosa-Guzman S.; TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007; 370 (9581): 49–58. doi: 10.1016/S0140-6736(07)61049-6.
  29. Corbett A.H., Lim M.L., Kashuba A.D. Kaletra (lopinavir/ritonavir). Ann. Pharmacother. 2002; 36 (7–8): 1193–1203. doi: 10.1345/aph.1A363.
  30. Shahar E., Moar C., Pollack S. Successful desensitization of enfuvirtide-induced skin hyper-sensitivity reaction. AIDS. 2005; 19 (4): 451–452. doi: 10.1097/01.aids.0000161779.23191.e5.
  31. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., Nadler J., Clotet B., Karlsson A., Wohlfeiler M., Montana J.B., McHale M., Sullivan J., Ridgway C., Felstead S., Dunne M.W., van der Ryst E., Mayer H.; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008; 359 (14): 1429–1441. doi: 10.1056/NEJMoa0803152.
  32. Dubois E.A., Cohen A.F. Maraviroc and raltegravir. Br. J. Clin. Pharmacol. 2009; 68 (5): 651–652. doi: 10.1111/j.1365-2125.2009.03503.x.
  33. Walmsley S.L., Antela A., Clumeck N., Duiculescu D., Eberhard A., Gutiérrez F., Hocqueloux L., Maggiolo F., Sandkovsky U., Granier C., Pappa K., Wynne B., Min S., Nichols G.; SINGLE Investi-gators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N. Engl. J. Med. 2013; 369 (19): 1807–1818. doi: 10.1056/NEJMoa1215541.
  34. Lee F.J., Carr A. Tolerability of HIV integrase inhibitors. Curr. Opin. HIV AIDS. 2012; 7 (5): 422–428. doi: 10.1097/COH.0b013e328356682a.
  35. Al Soub H., Al-Khal A.L.M., Alsoub D., Awouda W. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the treatment of HIV-infected patients: Experience with the first 100 patients from Qatar. Can. J. Infect. Dis. Med. Microbiol. 2020; 2020: 1597839. doi: 10.1155/2020/1597839.
  36. Nunn P., Brindle R., Wasunna K., Gilks C., Omwega M., Were J., Med M., Nunn P., Kibuga D., Ga¬thua S., Imalingat A., Nunn P., Wasunna K., Lucas S., McAdam K., Brindle R., Lucas S., Gilks C., Omwega M., Were J. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 1991; 337 (8742): 627–630. doi: 10.1016/0140-6736(91)92447-a.
  37. Grant A.D., Mngadi K.T., van Halsema C.L., Luttig M.M., Fielding K.L., Churchyard G.J. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS. 2010; 24 (Suppl. 5): 529–536. doi: 10.1097/01.aids.0000391019.10661.66.
  38. Garg Y., Gore R., Jain S., Kumar A. A rare case of isonia¬zid-induced erythroderma. Indian J. Pharmacol. 2015; 47 (6): 682–684. doi: 10.4103/0253-7613.169575.
  39. Savintseva E.V., Zelenina A.O., Shadieva S.V. Unwanted side effects and factors contri¬buting to their development, in the treatment of patients with first-time pulmonary tuberculosis. Sinergiya nauk. 2018; (24): 1224–1230. (In Russ.)
  40. Craig T.J., Peralta F., Boggavarapu J. Desensitization for fluconazole hypersensitivity. J. Allergy Clin. Immunol. 1996; 98 (4): 845–846. doi: 10.1016/s0091-6749(96)70136-7.
  41. McLaren P.J., Fellay J. HIV-1 and human genetic variation. Nat. Rev. Genet. 2021; 22: 645–657. doi: 10.1038/s41576-021-00378-0.
  42. Littera R., Carcassi C., Masala A., Piano P., Serra P., Ortu F., Corso N., Casula B., La Nasa G., Contu L., Manconi P.E. HLA-dependent hypersensitivity to nevira¬pine in Sardinian HIV patients. AIDS. 2006; 20 (12): 1621–1626. doi: 10.1097/01.aids.0000238408.82947.09.
  43. Vitezica Z.G., Milpied B., Lonjou C., Borot N., Ledger T.N., Lefebvre A., Hovnanian A. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008; 22 (4): 540–541. doi: 10.1097/QAD.0b013e3282f37812.

© 2021 Eco-Vector




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies